REFERENCES
1. Vissing CR, Axelsson Raja A, Helms AS, et al. Differences in disease trajectory, comorbidities, and mortality in sarcomeric and nonsarcomeric hypertrophic cardiomyopathy. Circulation. 2026;153:1104-16.
2. Maron BJ, Rowin EJ, Casey SA, Maron MS. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. JAMA Cardiol. 2016;1:98-105.
3. Fumagalli C, Bonanni F, Beltrami M, et al. Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring. Int J Cardiol. 2023;381:70-5.
4. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383:1305-16.
5. Harper AR, Goel A, Grace C, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet. 2021;53:135-42.
6. Mahmoud AK, Awad K, Sheashaa H, et al. Cardiovascular outcomes following bariatric surgery in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis. Am Heart J Plus. 2026;64:100756.
7. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010-20.
8. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1239-311.
